🇺🇸 FDA
Pipeline program

Gazyvaro 1,000 mg concentrate for solution for infusion.

APHP230848

Phase 2 small_molecule active

Quick answer

Gazyvaro 1,000 mg concentrate for solution for infusion. for Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials